PB28

[1]Amalia Azzariti, et al. Cyclohexylpiperazine Derivative PB28, a sigma2 Agonist and sigma1 Antagonist Receptor, Inhibits Cell Growth, Modulates P-glycoprotein, and Synergizes With Anthracyclines in Breast Cancer. Mol Cancer Ther. 2006 Jul;5 (7) :1807-16.|[2]Maria Laura Pati, et al. Sigma-2 Receptor Agonist Derivatives of 1-Cyclohexyl-4-[3- (5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl) propyl]piperazine (PB28) Induce Cell Death via Mitochondrial Superoxide Production and Caspase Activation in Pancreatic Cancer. BMC Cancer. 2017 Jan 13;17 (1) :51.|[3]Nicola A Colabufo, et al. A New Method for Evaluating sigma (2) Ligand Activity in the Isolated Guinea-Pig Bladder. Naunyn Schmiedebergs Arch Pharmacol. 2003 Aug;368 (2) :106-12.|[4]Francesco Berardi, et al. Exploring the Importance of Piperazine N-atoms for sigma (2) Receptor Affinity and Activity in a Series of Analogs of 1-cyclohexyl-4-[3- (5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl) propyl]piperazine (PB28) . J Med Chem. 2009 Dec 10;52 (23) :7817-28.|[5]David E Gordon, et al. A SARS-CoV-2-Human Protein-Protein Interaction Map Reveals Drug Targets and Potential Drug-Repurposing. bioRxiv. 2020 Mar 22;2020.03.22.002386.